Comparing the efficacy and safety of nafamostat mesylate versus citrate for anticoagulation in continuous renal replacement therapy: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Comparing the efficacy and safety of nafamostat mesylate versus citrate for anticoagulation in continuous renal replacement therapy: a systematic review and meta-analysis
Clinical Scorecard: Evaluating the Safety and Effectiveness of Nafamostat Mesylate Compared to Citrate for Anticoagulation in Continuous Renal Replacement Therapy: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Continuous Renal Replacement Therapy (CRRT)
Key Mechanisms
Nafamostat mesylate (NM) acts as a synthetic serine protease inhibitor, providing anticoagulant effects with a low bleeding risk.
Target Population
Critically ill patients receiving CRRT.
Care Setting
Intensive care units managing acute kidney injury.
Key Highlights
NM reduced the risk of bleeding events compared to citrate (RR = 0.54, p = 0.003).
No significant differences in filter lifespan or clotting events between NM and citrate.
Subgroup analyses indicated NM's effectiveness in high-risk bleeding scenarios.
Overall certainty of evidence is low to very low; further high-quality RCTs are needed.
NM is widely used in Asia, particularly Japan, for patients with high bleeding risk.
Guideline-Based Recommendations
Diagnosis
Management
Consider NM as an alternative anticoagulant for CRRT in patients with contraindications to citrate.
Monitoring & Follow-up
Risks
Monitor for bleeding events, especially in patients at high risk.
Patient & Prescribing Data
Critically ill patients with acute kidney injury requiring CRRT.
NM may be preferred in patients with a high risk of bleeding or contraindications to citrate.
Clinical Best Practices
Prioritize regional citrate anticoagulation (RCA) over heparin when possible.
Evaluate individual patient risk factors when selecting anticoagulation strategies.
